Palisade Bio Inc (PALI)

[Disquisition]

Under $4 now

[traderbbc1]

Can you amagine if they announced bad news.

[Disquisition]

Bidding $2.50

[$treet $inatra]

news is good, back to $10 in a few weeks

[$treet $inatra]

shorts and/or new issues... new ipo is easy to manipulate

[stock1ace1]

2.8 mill o/s where all these shares coming from ! ?

[Disquisition]

UNMITIGATED DUMPING

[traderbbc1]

Classic gap and trap.

[Disquisition]

DUMPED below $5

[$treet $inatra]

earnings aftermarket today.. accumulating at $5

[Disquisition]

Precisely.

[trendzone]

Looks like they turned the short lived pump into a toxic dump cesspool, like I have seen on many of these biotechnology stocks lately, they put out what seems like good news that brings in premarket sucker buyers and shorts panic and close, and than the dirtbags start an all day endless dilution game plan, and the trash shorts it down like a double edge sword twisted into the backs of longs.

[pilotnick]

In the near short term this will fly, so I got in and am going to buy more. I can wait for it to hit!

[Disquisition]

Just BRUTAL

[Disquisition]

This will close red.

[pilotnick]

get in on PALI that one is going to skyrocket!! Just did reverse merger and the value is with Leading Bio Sciences which is now PALI value is in the billions this is going to $250-$300 per share!

This is going to run up then split and continue doing that up to a market cap of around $2 billion!

[traderbbc1]

Good news! Maybe we can pair the losses from the past few days.

[Finditdotcom]

New coverage out ATTENTION: Premarket Breakout Alert: JRSS • PALI

Dear Fellow Trader,

JRSS and PALI is on immediate Alert!

Wall Street is Showing Major Interest in JRSS and PALI this Morning!

The trading session is just about to begin, so don't delay and pull them up on your trading screen before you miss out on another easy profitable day trading idea scenario.

Sincerely,
Editor In Chief, OTCtipReporter Team

[crudeoil24]

PALI is in FDA phase III clinical trials, > today fast track news.

[crudeoil24]

Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery
7:02 am ET May 13, 2021 (Benzinga) Print
Palisade Bio, Inc. (NASDAQ:PALI), a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the investigational drug LB1148, which has the potential to be the first oral treatment to reduce adhesions following abdominal or pelvic surgery. LB1148 was previously granted Fast Track Designation for the treatment of postoperative GI dysfunction associated with gut hypoperfusion injury in pediatric patients who have undergone congenital heart disease repair surgery in January 2021.

"Fast Track Designation represents another positive step for the clinical development of LB1148 and is a clear recognition of the serious need that exists for patients looking to avoid long-lasting and serious complications from post-surgical adhesions," said Tom Hallam, Ph.D., chief executive officer of Palisade Bio. "We look forward to working closely with the FDA to maintain an open dialogue about the clinical path forward with LB1148, not only for the reduction of surgical adhesions indication, but also in the other post-op indications where it is being investigated in the clinic. We believe that by reducing adhesions, LB1148 has the potential to benefit patients, physicians, hospitals, and payers alike."

[traderbbc1]

It's moving pre-market. You called it. What is the catalyst for the move.I see no news.

[pilotnick]

Get ready for this to takeoff!

[Disquisition]

do you mean run DOWN?

[traderbbc1]

Where do you see the pps in 12 months?

[traderbbc1]

It's running! Lower...OUCH

[ALERTS100%to10000%GAIN]

PALI 6.70 will run crazy here

[ALERTS100%to10000%GAIN]

PALI~~PIPELINE
Our initial focus is improving patients’ quality of life following major surgery by 1) accelerating postoperative return of gastrointestinal (GI) function to shorten their length of stay in the hospital and 2) prevention of post-surgical adhesions to reduce need for additional surgeries.

Additionally, we plan to pursue follow-on indications to address a myriad of health conditions and complications associated with chronic disruption of the intestinal mucosal barrier.

Our most advanced candidate, LB1143, is a Phase 3-ready oral protease inhibitor drug with the potential ability to protect intestinal integrity during and after surgery, representing a pipeline within a drug given the wide array of health complications that intestinal enzyme damage can cause.
https://www.palisadebio.com/pipeline/default.aspx

[ALERTS100%to10000%GAIN]

PALI~~WEBSITE~~https://www.palisadebio.com/about-us/about-us-overview/default.aspx